Transgelin, Human, clone 4G4
Monoclonal antibody HM2405 clone 4G4 recognizes human transgelin, also called SM-22. Transgelin is considered to be a biomarker for acute intestinal ischemia (AII) and leiomyosarcoma.
Read moreMonoclonal antibody HM2405 clone 4G4 recognizes human transgelin, also called SM-22.
Transgelin is a 22 kDa calponin-like protein and exists as different isoforms a-d based on different pH. It is a water-soluble protein which is abundantly expressed by intestinal smooth muscle tissues. Its role is not complete clear but it seems to play a role in differentiation and maturation of smooth muscle cells.
Transgelin is considered to be a biomarker for acute intestinal ischemia (AII) and leiomyosarcoma. AII is a relative rare abdominal emergency associated with considerable high morbidity and mortality as a consequence of obstruction of mesenteric blood flow associated with surgical procedures, hemorrhagic shock, trauma and sepsis. This leads to severe damage to the intestinal barrier and integrity. It is hypothesized that this transmural injury will lead to release of smooth muscle cell proteins like transgelin. Indeed, it has been shown that elevated levels of transgelin have been found in patients with transmural ischemia compared to controls.
The diagnosis of leiomyosarcoma is clinically important because it has been reported that soft tissue sarcomas showing a myoid differentiation, most often a smooth muscle differentiation, are more aggressive than those with no myoid differentiation. Transgelin correlates with smooth muscle differentiation. It was found that transgelin was one of the most represented in leiomyosarcomatous differentiation.
IHC-P: For fixation 4% formaldehyde was used and blocking was done with 5% BSA in PBS (Ref.2)
W: Both reduced and non-reduced western blot can be used. The expected band size is 22 kDa (Ref.1)
You may be interested in…
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA